Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis.

abstract：:Fibrin formed from fibrinogen is the main component of thrombi. Clot structure is characterized by fiber thickness and pore size, which differs within a given clot and between individuals. Plasma clot architecture is largely determined by the quantity and quality of fibrinogen. Plasma fibrinogen concentrations are mos...

journal_title：Seminars in thrombosis and hemostasis

authors： Undas A

更新日期：2016-06-01 00:00:00

abstract：:Molecular genetic analysis of families with hemophilia and other heritable bleeding disorders is a frequently requested laboratory investigation. In the United Kingdom, laboratories undertaking genetic testing must participate in a recognized external quality assessment scheme for formal accreditation. The UK National...

journal_title：Seminars in thrombosis and hemostasis

authors： Perry DJ,Cumming T,Goodeve A,Hill M,Jennings I,Kitchen S,Walker I

更新日期：2014-03-01 00:00:00

abstract：:Thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS) are thrombotic microangiopathies (TMAs) that can present in pregnancy. The presentation can be with typical microangiopathic features and thrombocytopenia, but there is also a significant risk of in-utero fetal loss. TTP presents m...

journal_title：Seminars in thrombosis and hemostasis

authors： Scully M

更新日期：2016-10-01 00:00:00

abstract：:The beta2-glycoprotein I (beta2-GPI) is known for its procoagulant as well as anticoagulant properties. The influence of beta2-GPI on tissue factor (TF) activity was investigated by chromogenic assays for both factor Xa generation and factor VIIa activity. When 1.36 mg/mL beta2-GPI was added to phospholipids prior to ...

journal_title：Seminars in thrombosis and hemostasis

authors： Ieko M,Yasukouchi T,Sawada KI,Koike T

更新日期：1998-01-01 00:00:00

abstract：:APC resistance is often associated with the occurrence of a single point mutation in factor V (factor VLeiden) at a predominant cleavage site for the natural anticoagulant, activated protein C (APC). In this article we will discuss the effects of this mutation (Arg506-->Gln) on the down-regulation of factor Va cofacto...

journal_title：Seminars in thrombosis and hemostasis

authors： Rosing J,Hemker HC,Tans G

更新日期：1998-01-01 00:00:00

abstract：:In the Netherlands, specialized care for patients with a bleeding disorder, including hemophilia, von Willebrand disease (VWD), and allied disorders, is concentrated in 13 Hemophilia Treatment Centers. The Dutch Hemophilia Treaters Society, the Dutch Hemophilia Nurses' Society, and the Netherlands Hemophilia Patients ...

journal_title：Seminars in thrombosis and hemostasis

authors： de Wee EM,Leebeek FW,Eikenboom JC

更新日期：2011-07-01 00:00:00

abstract：:Polycystic ovarian syndrome (PCOS) affects 12 to 19% of women and has reproductive and metabolic features (endothelial dysfunction, increased diabetes, and cardiovascular risk factors). It also appears to have altered coagulation and fibrinolysis with a prothrombotic state with epidemiological evidence of increased ve...

journal_title：Seminars in thrombosis and hemostasis

authors： Burchall GF,Piva TJ,Linden MD,Gibson-Helm ME,Ranasinha S,Teede HJ

更新日期：2016-02-01 00:00:00

abstract：:Platelets possess three P2 receptors: two (P2Y (1) and P2Y (12)) are receptors for adenosine diphosphate (ADP), and one (P2X1) is a receptor for adenosine triphosphate (ATP). The P2Y (1) receptor, which is coupled to Gq and phospholipase C-beta, is responsible for mobilization of ionized calcium from internal stores a...

journal_title：Seminars in thrombosis and hemostasis

authors： Cattaneo M

更新日期：2005-04-01 00:00:00

abstract：:Treatment of patients with inhibitors to FVIII remains a complex clinical problem. Although characterizing the individual patient may aid in the initial development of a care plan, no treatment is uniformly reliable for all patients. Experts in the field are as likely to disagree as agree when it comes to choosing tre...

journal_title：Seminars in thrombosis and hemostasis

authors： Macik BG

更新日期：1993-01-01 00:00:00

abstract：:Central venous catheters (CVCs) are important for the treatment of patients with cancer, especially in the perioperative and palliative care settings. These devices not only allow for the administration of chemotherapy, parenteral nutrition, and other intravenous therapies, but they may also improve the patients' qual...

journal_title：Seminars in thrombosis and hemostasis

authors： Linnemann B

更新日期：2014-04-01 00:00:00

abstract：:Clotting activation occurs frequently in cancer. Tissue factor (TF), the most potent initiator of coagulation, is expressed aberrantly in many types of malignancy and is involved not only in tumor-associated hypercoagulability but also in promoting tumor angiogenesis and metastasis via coagulation-dependent and coagul...

journal_title：Seminars in thrombosis and hemostasis

authors： Amirkhosravi A,Meyer T,Amaya M,Davila M,Mousa SA,Robson T,Francis JL

更新日期：2007-10-01 00:00:00

abstract：:A prospective randomized double-blind trial was performed comparing conventional low-dose heparin with a LMWH fragment (Kabi 2165, Fragmin) for thromboprophylaxis in elective general abdominal surgical patients. The first dose of the fragment was given in the evening before surgery, and thereafter every evening. There...

journal_title：Seminars in thrombosis and hemostasis

authors： Bergqvist D,Burmark US,Frisell J,Guilbaud O,Hallböök T,Horn A,Lindhagen A,Ljungner H,Ljungström KG,Mätzsch T

更新日期：1990-10-01 00:00:00

abstract：UNLABELLED:We present 25-year experience with inhibitors in previously untreated patients (PUPs) with severe hemophilia A in Slovakia, where safe factor VIII (FVIII) concentrates have been used since 1990. A prospective study focused on inhibitor incidence in PUPs was established in 1997. Out of a total 61 PUPs born be...

journal_title：Seminars in thrombosis and hemostasis

authors： Batorova A,Jankovicova D,Morongova A,Bubanska E,Prigancova T,Horakova J,Machyniakova M,Cervenka J,Chandoga J,Böhmer D,Mistrik M

更新日期：2016-07-01 00:00:00

abstract：:Protein S is a vitamin K-dependent plasma glycoprotein circulating in plasma at a concentration of around 350 nM. Approximately 60% of protein S in human plasma is bound to the complement regulatory protein C4b-binding protein (C4BP) in a high-affinity, high-molecular-weight complex. Protein S in plasma has multiple a...

journal_title：Seminars in thrombosis and hemostasis

authors： Dahlbäck B

更新日期：2018-03-01 00:00:00

abstract：:The two components of biological variability are interindividual variability, which is the variability due to the heterogeneity of physiologic influences among subjects, and intraindividual variability, which is due to the variability in the same individual over time. Analysis of biological variation is crucial for es...

journal_title：Seminars in thrombosis and hemostasis

authors： Banfi G,Del Fabbro M

更新日期：2009-02-01 00:00:00

abstract：:Asymptomatic pulmonary embolism (PE) is present in at least one-third of patients with deep venous thrombosis (DVT). However, knowledge about its influence on the prognosis of patients is limited. The aim of this study was to assess the prognostic impact of asymptomatic PE in patients with DVT and to explore risk fact...

journal_title：Seminars in thrombosis and hemostasis

authors： Boc A,Vene N,Košmelj K,Mavri A

更新日期：2017-02-01 00:00:00

abstract：:The average age of the US population continues to increase. Age is the most important determinant of disease and disability in humans, but the fundamental mechanisms of aging remain largely unknown. Many age-related diseases are associated with an impaired fibrinolytic system. Elevated plasminogen activator inhibitor-...

journal_title：Seminars in thrombosis and hemostasis

authors： Eren M,Boe AE,Klyachko EA,Vaughan DE

更新日期：2014-09-01 00:00:00

abstract：:Atherosclerosis is the major underlying cause of cardiovascular diseases, the prevalence of which is continuously increasing, thus currently standing as the leading global cause of death. This pathology gradually develops over the course of 50 or more years throughout the life of an individual under the influence of a...

journal_title：Seminars in thrombosis and hemostasis

authors： Larivière M,Bonnet S,Lorenzato C,Laroche-Traineau J,Ottonès F,Jacobin-Valat MJ,Clofent-Sanchez G

更新日期：2020-07-01 00:00:00

abstract：:Point-of-care (POC) testing in hemostasis has experienced a significant increase in the spectrum of available tests and the number of tests performed. Short turn-around time and observation of rapid changes in test results are facilitated. The quality control process in POC testing must encompass a preanalytic (collec...

journal_title：Seminars in thrombosis and hemostasis

authors： Fries D,Streif W

更新日期：2015-02-01 00:00:00

abstract：:Oral anticoagulants (OAs) are the drugs of choice for the prevention of recurrence and death in patients with venous thromboembolism (VTE). Oral anticoagulant treatment (OAT) aims to retard blood coagulation to obtain maximum protection against thromboembolic events with the lowest risk of bleeding. The intensity of O...

journal_title：Seminars in thrombosis and hemostasis

authors： Pengo V

更新日期：2006-11-01 00:00:00

abstract：:Type 2B von Willebrand disease (VWD2B) is a rare, autosomal-dominant inherited bleeding disorder, characterized by an enhanced ristocetin-induced platelet aggregation in platelet-rich plasma and often with variable degree of thrombocytopenia and loss of high-molecular-weight multimers von Willebrand factor (VWF). All ...

journal_title：Seminars in thrombosis and hemostasis

authors： Castaman G,Federici AB

更新日期：2016-07-01 00:00:00

abstract：:Biological rhythms are a universal phenomenon in living organisms and serve to help organisms adapt within a circadian cycle to the 24-hour-oscillating environment. The rhythmic modulation of selective pathways thus enables organisms to optimize their ability to store and generate chemical energy, to minimize environm...

journal_title：Seminars in thrombosis and hemostasis

authors： Montagnana M,Salvagno GL,Lippi G

更新日期：2009-02-01 00:00:00

abstract：:From injury through healing, thrombin has several important functions in blood clotting, subsequent clot lysis, and tissue repair. These include edema, inflammation, cell recruitment, cellular releases, transformations, mitogenesis, and angiogenesis. Thrombin also participates in disease states, such as venous thrombo...

journal_title：Seminars in thrombosis and hemostasis

authors： Fenton JW 2nd,Ofosu FA,Brezniak DV,Hassouna HI

更新日期：1998-01-01 00:00:00

abstract：:Essential thrombocythemia (ET) is a clonal myeloproliferative disorder of unknown origin primarily involving the megakaryocyte/platelet lineage. In an attempt to evaluate the role of the receptor c-mpl and its ligand thrombopoietin (TPO) in ET, various studies have been undertaken, the results of which are discussed h...

journal_title：Seminars in thrombosis and hemostasis

authors： Griesshammer M,Bangerter M,Schrezenmeier H

更新日期：1997-01-01 00:00:00

abstract：:Natural inhibitors of coagulation, in other words, antithrombin (AT), the protein C system, and tissue factor pathway inhibitor (TFPI), play an important role in controlling the activation of coagulation during disseminated intravascular coagulation (DIC). Furthermore, they may not only influence coagulation but also ...

journal_title：Seminars in thrombosis and hemostasis

authors： de Jonge E,van der Poll T,Kesecioglu J,Levi M

更新日期：2001-12-01 00:00:00

abstract：:Clinicians prescribing new oral anticoagulants (OACs; dabigatran, rivaroxaban, and apixaban) should be aware of the exclusion criteria related to bleeding risks defined in published clinical studies. At least a quarter of patients currently using warfarin have an exclusion criterion that may prevent easy transition to...

journal_title：Seminars in thrombosis and hemostasis

authors： Salmela B,Joutsi-Korhonen L,Armstrong E,Lassila R

更新日期：2012-02-01 00:00:00

abstract：:The prothrombin time (PT) assay is the most clinically ordered coagulation test and is most often used for monitoring of vitamin K antagonist (VKA) therapy (e.g., warfarin), where results are expressed as an international normalized ratio (INR). The INR is in essence the patient's PT "mathematically adjusted" to a sta...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ,Adcock DM

更新日期：2008-10-01 00:00:00

abstract：:The risk for arteriosclerosis and thrombosis of patients with severe hyperhomocysteinemia is reduced by homocysteine-lowering therapy. Whether this is the case in patients with mild hyperhomocysteinemia remains to be proved. Another challenge for researchers is to establish a satisfying pathological mechanism of the v...

journal_title：Seminars in thrombosis and hemostasis

authors： Blom HJ

更新日期：2000-01-01 00:00:00

abstract：:CD34 (+) progenitor cells are a promising source of regeneration in atherosclerosis or ischemic heart disease. However, as recently published, CD34(+) progenitor cells have the potential to differentiate not only into endothelial cells but also into foam cells upon interaction with platelets. The mechanism of platelet...

journal_title：Seminars in thrombosis and hemostasis

authors： Seizer P,Schiemann S,Merz T,Daub K,Bigalke B,Stellos K,Müller I,Stöckle C,Müller K,Gawaz M,May AE

更新日期：2010-03-01 00:00:00

abstract：:In addition to the criteria of the Polycythemia Vera Study Group, positive markers for essential thrombocythemia (ET) include spontaneous BFU-E, splenomegaly, and megakaryocyte morphology in bone marrow smears and biopsy material. The hematologic features of 11 reported cases of ET in childhood showed platelet counts ...

journal_title：Seminars in thrombosis and hemostasis

authors： Michiels JJ,Van Genderen PJ

更新日期：1997-01-01 00:00:00